Summary
The MCF-7 cell S9 fraction and whole MCF-7 cells can mediate one-electron-redox cycling of doxorubicin, giving rise to concomitant oxidation of reduced nicotinamide adenine dinucleotide phosphate (NADPH), formation of a drug semiquinone free radical, consumption of molecular oxygen and formation of superoxide anions and hydroxyl radicals. Doxorubicin redox cycling was consistent with DNA strand breakage and cell kill in MCF-7 cells. In contrast, no evidence for redox cycling was found for mitoxantrone (MIT), CI941 or ametantrone (AMET) in MCF-7 cells. Despite the absence of redox cycling, the CI941, MIT, and AMET concentrations resulting in 50% mortality (LC50; 1.5×10−10, 5.2×10−9 and 1.2×10−6 m, respectively) of MCF-7 cells were lower than that of DOX (3.0×10−6 m). Furthermore, the higher cytotoxicity of MIT and CI941 as compared with AMET or DOX was associated with greater efficiency in inducing DNA strand breakage in MCF-7 cells as determined by alkaline elution. Sine MIT and CI941 proved to be the most potent DNA-damaging and cytotoxic agents in this study, the ability of DOX to undergo redox cycling does not appear to confer increased cytotoxic potential on this agent. The present study revealed several important aspects with regards to the structural modification of anthraquinone antitumour agents. Firstly, the C1 and C4 postitioning of the hydroxyethylamino side chains on MIT, CI941 and AMET is associated with a lack of flavin reductase-mediated activation of these agents. Secondly, the possession of a C5 or C8 aromatic hydroxyl group appears to be intimately involved in the enhanced DNA strand breakage and cytotoxic potency of MIT and CI941, since AMET does not possess these groups. These findings indicate that future development of quinone antitumour agents should concentrate on compounds that do not undergo redox cycling but do possess aromatic hydroxyl groups, since the latter appear to be responsible for the enhanced cytotoxicity of MIT and CI941.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- DOX:
-
doxorubicin
- MIT:
-
mitoxantrone
- AMET:
-
ametantrone
- SOD:
-
superoxide dismutase
- DMPO:
-
5,5-dimethyl-1-pyrroline-N-oxide
- ESR:
-
electron spin resonance
- SSF:
-
strand scission factor
References
Allan SG, Cummings J, Evans S, Nicolson M, Stewart ME, Cassidy J, Soukop M, Kaye SB, Smyth JF (1991) Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology. Cancer Chemother Pharmacol 28: 55
Azzi A, Montecucco C, Richter C (1975) The use of acetylated cytochrome c for detection of superoxide radicals produced in biological membranes. Biochem Biophys Res Commun 65: 597
Bachur NR, Gordon SL, Gee MV (1978) A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38: 1745
Basra J (1986) A study of free radical formation in liver and heart tissue by alkylaminoanthraquinone antitumour agents based on mitoxantrone. PhD Thesis, Leicester Polytechnic
Basra J, Wolf CR, Brown JR, Patterson LH (1985) Evidence for human liver mediated free a radical formation by doxorubicin and mitoxantrone. Anticancer Drug Design 1: 45
Bellamy WT, Dorr RT, Dalton WS, Alberts DS (1988) Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration. Cancer Res 48: 6360
Capolongo L, Belvedere G, D'Incalci M (1990) DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and-resistant human colon carcinoma cells. Cancer Chemother Pharmacol 25: 430
Capranico D, De Isabella P, Penco S, Tinelli S, Zunino F (1989) Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin and 4-demethyl-6-deoxydoxorubicin in murine leukaemia P388 cells. Cancer Res 49: 2022
Crespi MD, Ivanier SE, Genovese J, Baldi A (1986) Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochim Biophys Acta 136: 521
Dalton WS, Cress AE, Alberts DS, Trent JM (1988) Cytogenic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 48: 1882
Deffie AM, Batra JK, Goldenberg GJ (1989) Direct correlation between DNA topoisomerase II activity anc cytotoxicity in Adriamycin-sensitive and-resistant P388 leukemia cell lines. Cancer Res 49: 58
De Jong S, Zijlstra JG, De Vries EGE, Mulder NH (1990) Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an Adrianycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304
Doroshow J (1986) Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cell by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun 135: 330
Doroshow JH, Akman S, Esworthy S, Chu FF, Burke T (1991) Doxorubicin resistance conferred by selective enhancement of intracellular glutathione peroxidase or superoxide dismutase content in human MCF-7 breast cancer cells. Free Radical Res Commun 12–13: 779
Drewinko B, Yang L-Y, Bartogie B, Trujillo JM (1983) Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate and doxorubicin in human cells in vitro. Cancer Res 43: 2648
Ellis AL, Randolph JK, Conway BR, Gewirtz DA (1990) Biochemical lesions associated with the antiproliferative effects of mitoxantrone in the hepatoma cell. Biochem Pharmacol 39: 1549
Epstein RJ, Smith PJ (1988) Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumour drugs. Cancer Res 48: 297
Faulds D, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41: 400
Fisher GR, Gutierrez PL (1991) The reductive metabolism of diaziquone in the S9 fraction of MCF-7 cells; free radical formation and NAD(P)H (quinone-acceptor) oxidoreductase (DT-diaphorase) activity. Free Radicals Biol Med 10: 359
Fisher GR, Patterson LH (1988) Free radical formation by doxorubicin in MCF-7 human breast cancer cells. J Pharma Pharmacol 40 [Suppl]: 28
Fisher GR, Patterson LH (1989) A comparison of free radical generation by doxorubicin and CI941 in MCF-7 human breast cancer cells. Br J Cancer 60: 476
Fisher GR, Patterson LH (1990) DNA strand breakage by peroxidase-activated mitoxantrone. J Pharm Pharmacol 43: 65
Fisher GR, Brown JR, Patterson LH (1989) Redox cycling in MCF-7 human breast cancer cells by antitumour agents based on mitozantrone. Free Radical Res Commun 7: 221
Fisher GR, Maine JE, Patterson LH (1989) Comparison of free radical generation by doxorubicin and mitoxantrone in MCF-7 human breast cancer cells. J Pharm Pharmacol 41 [Suppl]: 23P
Fisher GR, Brown JR, Patterson LH (1990) Involvement of hydroxyl radical formation and DNA strand breakage in the cytotoxicity of anthraquinone antitumour agents. Free Radical Res Commun 11: 117
Fisher GR, Maine JE, Patterson LH (1990) Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone and CI941: comparison with doxorubicin. Proc Am Assoc Cancer Res 31: 397
Fox ME, Smith PJ (1990) Long term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumour DNA intercalators mAMSA and mitoxantrone. Cancer Res 50: 5813
Gandecha BM (1985) Development of potential antitumour agents based on considerations of the mode of action and pharmacokinetics of daunomycin and doxorubicin. PhD Thesis, Leicester Polytechnic
Gianni L, Cordon BJ, Myers CE (1983) The biochemical basis of anthracycline toxicity and antitumour activity. Rev Biochem Toxicol 5: 1
Graham MA, Newell, DR, Butler J, Hoey B, Patterson LH (1987) The effect of the anthrapyrazole antitumour agent CI941 on rat liver microsome and cytochrome P450 reductase mediated free radical processes. Biochem Pharmacol 36: 3345
Hartley JA, Reszka K, Zuo ET, Wilson WD Morgan AR, Lown JW (1988) Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids; structural requirements for DNA binding, intercalation and photosensitization. Mol Pharm 33: 265
Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W (1988) Mitoxantrone-induced DNA damage in leukaemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 22: 205
Ho AD, Seither E, Ma DDF, Prentice HG (1987) Mitoxantrone-induced toxicity and DNA strand breaks in leukaemic cells. Br J Haematol 65: 51
Iliakis, Lazaar W (1987) Effect of sodium chloride concentration on Adriamycin andN-trifluoroacetyladriamycin-14-valerate (AD32)-induced cell killing and DNA damage in Chinese hamster ovary cells. Cancer Res 47: 1853
Inaba K, Johnson RK (1978) Uptake and retention of Adriamycin and daunorubicin by sensitive and anthracycline resistant sublines of P388 leukaemia. Biochem Pharmacol 27: 2123
Johnson RK, Zee-Cheng RK-Y, Lee WW, Acton EM, Henry DW, Cheng CC (1979) Experimental antitumour activity of anthraquinones. Cancer Treat Rep 63: 425
Johnston JB, Zwelling LA, Kerrigan D, Lloyd LS, Glazer RI (1983) Comparison of DNA scission and cytotoxicity produced by Adriamycin and 5-iminodaunorubicin in human colon carcinoma cells. Biochem Pharmacol 32: 2253
Judson IR (1991) Amthrapyrazoles: true successors to the anthracylines? Anti-Cancer Drugs 2: 223
Kapuscinski J, Darzynkiewicz Z (1986) Relationship between the pharmacological activity of antitumour drugs ametantrone and mitoxantrone (Novantrone) and their ability to condense nucleic acids. Proc Natl Acad Sci USA 83: 6302
Kharasch ED, Novak RF (1982) Inhibition of Adriamycin-stimulated microsomal lipid peroxidation by mitoxantrone and ametantrone, two new antineoplastic agents. Biochem Biophys Res Commun 108: 1346
Kharasch ED, Novak RF (1983) bis(Alkylamino)anthracenedione antineoplastic agent metabolic activation by NADPH cytochrome P450 reductase and NADH dehydrogenase: diminshed activity relative to anthracyclines. Arch Biochem Biophys 224: 682
Kharasch ED, Novak RF (1985) Mitoxantrone: propensity for free radical formation and lipid peroxidation — implications for cardiotoxicity. Invest New Drugs 3: 95
Kohn KW, Erickson LC, Ewig RAG, Friedman CA (1976) Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry 15: 4629
Lawrence TS (1988) Reduction of doxorubicin cytotoxicity by oubain: correlation with topoisomerase-induced DNA strand breakage in human and hamster cells. Cancer Res 48: 725
Locher SE, Meyn RE (1981) Relationship between cytotoxicity and DNA damage in mammalian cells treated with anthracenedione derivatives. Chem-Biol Interact 46: 369
Murdock KC, Wallace RE, Durr FE, Child FE, Citarella RV, Fabio PF, Angier RB (1979) Antitumour agents: I. 1,4-bis(Aminoalkylamino)-9,10-anthracenediones. J Med Chem 22: 1024
Nishio A, Uyeki FM (1983) Cellular uptake and inhibition of DNA synthesis by dihydroxyanthraquinone and 2 analogues. Cancer Res 43: 1951
Panneerealvam M, Bredehorst R, Vogel C-W (1987) Resistance of human melanoma cells against the cytotoxic and complement-enhancing activities of doxorubicin. Cancer Res 47: 4607
Partridge MBR (1987) A study of the in vitro cytotoxicity of alkylaminoanthraquinone antitumour agents based on mitoxantrone and doxorubicin. PhD Thesis, Leicester Polytechnic
Pincus R, Goldman D (1990) Evidence for impaired mitoxantrone and vinblastine binding in P388 murine leukaemia cells with multidrug resistance. Biochem Pharmacol 40: 2625
Potmesil M, Kirschenbaum S, Israel M, Levin M, Khetarpal VK, Silber R (1983) Relationship of Adriamycin concentrations to the DNA lesions induced in hypoxic and euoxic L1210 cells. Cancer Res 43: 3528
Potmesil M, Israel M, Silber R (1984) Two mechanisms of Adriamycin-DNA interaction in L1210 cells. Biochem Pharmacol 33: 3137
Reska K, Kolodziejczk P, Lown JW (1986) Horseradish peroxidase-catalysed oxidation of mitoxantrone: spectrophotometric and electron paramagnetic studies. Free Radicals Biol Med 2: 25
Reska K, Hartley JA, Kolodziejczyk P, Lown JW (1989) Interaction of the peroxidase-derived metabolite of mitoxantrone with nucleic acids: evidence for covalent binding of14C-labeled drug. Biochem Pharmacol 38: 4253–4260
Roberts RA, Cress AE, Dalton WS (1989) Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. Biochem Pharmacol 38: 4283
Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone: a new anticancer drug with significant clinical activity. Annals Internal Medicine 105: 567
Showalter HDH, Fry DW, Leopold WR, Lown JW, Plambeck JA, Reszka K (1986) Design, biochemical pharmacology, electrochemistry and tumour biology of antitumour anthrapyrazoles. Anticancer Res 1: 73
Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE (1987) Differential formation of hydroxyl radicals by Adriamycin in sensitive and resistant human breast tumour cells: implications for the mechanism of action. Biochemistry 26: 3776
Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE (1987) Adriamycin-stimulated hydroxyl radical formation in human breast tumour cells. Biochem Pharmacol 36: 793
Skovsgaard T (1978) Carrier mediated transport of daunorubicin, Adriamycin and rubidazone in Ehrlich ascites tumour cells. Biochem Pharmacol 27: 1221
Smith PJ, Morgan SA, Fox ME, Watson JV (1990) Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmacol 40: 2069
Stout DL, Becker FF (1982) DNA single strand fluorimetric quantitation after alkaline elution. Anal Biochem 127: 302
Taylor RF, Teague LA, Yesair DW (1981) Drug-binding macromolecular lipids from L1210 leukaemia tumours. Cancer Res 41: 4316
Tewey KM, Rowe TC, Yang L, Halligan DBD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerse II. Science 226: 466
Turner MJ III, Everman DB, Ellington SP, Fields CE (1990) Detection of free radicals during the cellular metabolism of Adriamycin. Free Radicals Biol Med 9: 415
Wallace RE, Lindh D, Durr FE (1987) Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro. Cancer Invest 5: 417
Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54: 665
White RJ, Durr FE (1985) Development of mitoxantrone. Invest New Drugs 3: 85
Zwelling LA, Michael S, Erickson LC, Ungerleider RS, Nichols M (1981) Protein associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4′-(9-acridinylamino)methanesulfon-m-anisidide and Adriamycin. Biochemistry 20: 6553
Author information
Authors and Affiliations
Additional information
This work was funded by the Cancer Research Campaign (UK)
Rights and permissions
About this article
Cite this article
Fisher, G.R., Patterson, L.H. Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin. Cancer Chemother. Pharmacol. 30, 451–458 (1992). https://doi.org/10.1007/BF00685596
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685596